OMED OncoMed Pharmaceuticals Inc.

0.8
+0.01  (+1%)
Previous Close 0.79
Open 0.79
Price To Book 0.6
Market Cap 30923431
Shares 38,630,145
Volume 1,680,998
Short Ratio
Av. Daily Volume 296,581

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 17, 2017 - primary endpoint not met.
Tarextumab - PINNACLE trial
Small cell lung cancer
Company announced late January 2016 that they plan to unblind the trial following notice from the DSMB that suggests a low likelihood of a statistically significant benefit in overall survival. Subsequently, in February 2016 an announcement was made to discontine the trial
Tarextumab ALPINE
Pancreatic Cancer
Phase 1b data ESMO October 2018 noted PFS 5.4 months.
Navicixizumab
Ovarian cancer
Data from Phase 1a portion due at SITC November 9, 2018. SD 39%.
Anti-TIGIT (OMP-313M32)
Solid tumors
Phase 1a data due 2019.
GITRL-Fc (OMP-336B11)
Locally Advanced or Metastatic Tumor

Latest News

  1. IPOs, M&A, and Dividends: Taking A Look At Year-End News Catalysts
  2. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  3. This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
  4. Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
  5. Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences — Renewed Outlook, Key Drivers of Growth
  6. OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
  7. OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its Industry
  8. OncoMed: 3Q Earnings Snapshot
  9. OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
  10. OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
  11. OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
  12. OncoMed Announces Publication of Phase 1a Data of Navicixizumab
  13. OncoMed Provides Update on Navicixizumab Partnership
  14. Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?
  15. OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates